Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Net Cash Flow came in at -$496000.0 in Q2 2026, down 100.75% YoY from $66.1 million in Q2 2025, and down 100.82% on a QoQ basis from $60.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Net Cash Flow data on file, last reported at -$496000.0 in Q2 2026.
- Quarterly Net Cash Flow fell 100.75% year-over-year to -$496000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $609.8 million (up 479.16% YoY) and the FY2025 annual result came in at $655.2 million, up 287.69% from the prior year.
- Net Cash Flow declined to -$496000.0 in Q2 2026, from $60.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $495.6 million in Q3 2022 to a low of -$283.7 million in Q1 2022.
- A 5-year average of $48.8 million and a median of $44.9 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 150.73% — and 2024, when it surged 2124.43%.
- Tracing ALNY's Net Cash Flow over 5 years: stood at -$208.5 million in 2022, then declined by 10.92% to -$231.2 million in 2023, then soared by 49.58% to -$116.6 million in 2024, then surged by 247.29% to $171.7 million in 2025, then tumbled by 100.29% to -$496000.0 in 2026.
- The last three Net Cash Flow figures came in at -$496000.0 (Q2 2026), $60.7 million (Q1 2026), and $171.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -496,000.00 |
| Jun 30, 2026 | -496,000.00 |
| Mar 31, 2026 | 60.68 Mn |
| Mar 31, 2026 | 60.68 Mn |
| Dec 31, 2025 | 171.71 Mn |
| Dec 31, 2025 | 171.71 Mn |
| Sep 30, 2025 | 377.87 Mn |
| Sep 30, 2025 | 377.87 Mn |
| Jun 30, 2025 | 66.11 Mn |
| Jun 30, 2025 | 66.11 Mn |
| Mar 31, 2025 | 39.54 Mn |
| Mar 31, 2025 | 39.54 Mn |
| Dec 31, 2024 | -116.58 Mn |
| Dec 31, 2024 | -116.58 Mn |
| Sep 30, 2024 | 116.21 Mn |
| Sep 30, 2024 | 116.21 Mn |
| Jun 30, 2024 | 289.59 Mn |
| Jun 30, 2024 | 289.59 Mn |
| Mar 31, 2024 | -120.22 Mn |
| Mar 31, 2024 | -120.22 Mn |